Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Platelet
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
====Inhibition==== Factors from the lining of vessels stop platelets from activating. An intact endothelial lining ''inhibits'' platelet activation by producing [[nitric oxide]], endothelial-[[apyrase|ADPase]], and [[prostacyclin|PGI<sub>2</sub>]] (prostacyclin). Endothelial-ADPase degrades the platelet activator [[adenosine diphosphate|ADP]].{{citation needed|date=December 2021}} Resting platelets maintain active calcium [[efflux (microbiology)|efflux]] via a [[cyclic AMP]]-activated calcium pump. Intracellular calcium concentration determines platelet activation status, as it is the [[second messenger]] that drives platelet conformational change and degranulation. Endothelial [[prostacyclin]] binds to [[prostacyclin receptor|prostanoid]] receptors on the surface of resting platelets. This event stimulates the coupled [[Gs alpha subunit|Gs]] protein to increase [[adenylate cyclase]] activity and increases the production of cAMP, further promoting the efflux of calcium and reducing intracellular calcium availability for platelet activation.{{citation needed|date=December 2021}} ADP on the other hand binds to [[purinergic receptor]]s on the platelet surface. Since the thrombocytic purinergic receptor [[P2Y12]] is coupled to [[Gi alpha subunit|Gi]] proteins, ADP reduces platelet adenylate cyclase activity and cAMP production, leading to accumulation of calcium inside the platelet by inactivating the cAMP calcium efflux pump. The other ADP-receptor [[P2Y1]] couples to Gq that activates phospholipase C-beta 2 ([[PLCB2]]), resulting in [[inositol 1,4,5-trisphosphate]] (IP3) generation and intracellular release of more calcium. This together induces platelet activation. Endothelial ADPase degrades ADP and prevents this from happening. [[Clopidogrel]] and related antiplatelet medications also work as purinergic receptor [[P2Y12]] [[receptor antagonist|antagonists]].{{citation needed|date=December 2021}} Data suggest that ADP activates the [[PI3K/Akt]] pathway during a first wave of aggregation, leading to thrombin generation and [[protease-activated receptor 1|PARβ1]] activation, which evokes a second wave of aggregation.<ref name="JiangXu2013">{{cite journal |last1=Jiang |first1=L. |last2=Xu |first2=C. |last3=Yu |first3=S. |last4=Liu |first4=P. |last5=Luo |first5=D. |last6=Zhou |first6=Q. |last7=Gao |first7=C. |last8=Hu |first8=H. |title=A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation |journal=Journal of Thrombosis and Haemostasis |volume=11 |issue=5 |year=2013 |pages=930β940 |issn=1538-7933 |doi=10.1111/jth.12168 |pmid=23406164 |doi-access=free}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)